Terug
17
Dagbereik
€ 20,44
€ 20,98
52-Weeksbereik
€ 11,84
€ 24,99
Volume
635.771
50D / 200D Gem.
€ 20,72
/
€ 18,21
Vorige Slotkoers
€ 20,60
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (627 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 10,8 | 0,3 |
| P/B | 2,1 | 2,9 |
| ROE % | 20,3 | 3,7 |
| Net Margin % | 8,6 | 3,8 |
| Rev Growth 5Y % | 0,0 | 10,0 |
| D/E | 0,8 | 0,2 |
Koersdoel Analisten
Hold
€ 20,67
-0.4%
Low: € 19,00
High: € 22,00
Forward K/W
9,2
Forward WPA
€ 2,24
WPA Groei (sch.)
+0,0%
Omzet Sch.
1,9 B
Winstschattingen
| Periode | WPA Sch. | Omzet Sch. | Analisten |
|---|---|---|---|
| FY2029 |
€ 2,05
€ 2,01 – € 2,09
|
2,2 B | 1 |
| FY2028 |
€ 2,27
€ 2,07 – € 2,41
|
2,1 B | 3 |
| FY2027 |
€ 2,33
€ 2,21 – € 2,44
|
2 B | 5 |
Belangrijkste Punten
Revenue grew 0,03% annually over 5 years — modest growth
ROE of 20,28% indicates high profitability
Generating 252,63M in free cash flow
P/E of 10,77 — trading at a low valuation
Revenue growth is decelerating — 1Y growth trails 5Y average by 4,95%
Cash machine — converts 152,75% of earnings into free cash flow
Groei
Revenue Growth (5Y)
0,03%
Revenue (1Y)-4,92%
Earnings (1Y)N/A
FCF Growth (3Y)55,86%
Kwaliteit
Return on Equity
20,28%
ROIC11,36%
Net Margin8,64%
Op. Margin12,07%
Veiligheid
Debt / Equity
0,76
Current Ratio1,66
Interest Coverage6,43
Waardering
P/E Ratio
10,77
P/B Ratio2,06
EV/EBITDA8,94
Dividend Yield0,00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | -4,92% | Revenue Growth (3Y) | -2,05% |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | 0,03% | Earnings Growth (5Y) | 6,01% |
| Profitability | |||
| Revenue (TTM) | 1,91B | Net Income (TTM) | 165,39M |
| ROE | 20,28% | ROA | 7,36% |
| Gross Margin | 24,66% | Operating Margin | 12,07% |
| Net Margin | 8,64% | Free Cash Flow (TTM) | 252,63M |
| ROIC | 11,36% | FCF Growth (3Y) | 55,86% |
| Safety | |||
| Debt / Equity | 0,76 | Current Ratio | 1,66 |
| Interest Coverage | 6,43 | Dividend Yield | 0,00% |
| Valuation | |||
| P/E Ratio | 10,77 | P/B Ratio | 2,06 |
| P/S Ratio | 0,93 | PEG Ratio | -0,04 |
| EV/EBITDA | 8,94 | Dividend Yield | 0,00% |
| Market Cap | 1,78B | Enterprise Value | 2,07B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 1,91B | 2,01B | 1,99B | 1,97B | 1,91B |
| Net Income | 165,39M | -99,07M | -60,41M | 66,34M | 130,96M |
| EPS (Diluted) | 1,94 | -1,19 | -0,73 | 0,79 | 1,52 |
| Gross Profit | 471,88M | 454,34M | 421,57M | 467,03M | 513,24M |
| Operating Income | 231,09M | -68,71M | 7,32M | 172,69M | 202,92M |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 2,25B | 2,15B | 2,22B | 2,35B | 2,72B |
| Total Liabilities | 1,38B | 1,39B | 1,37B | 1,46B | 1,83B |
| Shareholders' Equity | 865,85M | 764,94M | 849,06M | 891,63M | 896,49M |
| Total Debt | 660,30M | 662,31M | 701,65M | 717,08M | 1,07B |
| Cash & Equivalents | 375,24M | 229,94M | 73,26M | 9,82M | 387,39M |
| Current Assets | 763,51M | 639,61M | 483,45M | 427,99M | 840,56M |
| Current Liabilities | 458,91M | 434,11M | 388,95M | 426,98M | 427,37M |
Strategiescores
This stock passed the criteria for 1 strategy
Score = fit strength (0–100)
Rank = position among all matches
#461 of 670
Recente Activiteit
Ingestapt
Contrarian Investing (David Dreman)
Mar 24, 2026